CN117957000A - 药物组合物及其用途 - Google Patents

药物组合物及其用途 Download PDF

Info

Publication number
CN117957000A
CN117957000A CN202280061191.5A CN202280061191A CN117957000A CN 117957000 A CN117957000 A CN 117957000A CN 202280061191 A CN202280061191 A CN 202280061191A CN 117957000 A CN117957000 A CN 117957000A
Authority
CN
China
Prior art keywords
pharmaceutically acceptable
acceptable salt
vomertinib
egfr
pharmaceutical composition
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN202280061191.5A
Other languages
English (en)
Chinese (zh)
Inventor
罗会兵
李庆
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Shanghai Allist Medicine Polytron Technologies Inc
Original Assignee
Shanghai Allist Medicine Polytron Technologies Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Shanghai Allist Medicine Polytron Technologies Inc filed Critical Shanghai Allist Medicine Polytron Technologies Inc
Publication of CN117957000A publication Critical patent/CN117957000A/zh
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Epidemiology (AREA)
  • Oncology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
CN202280061191.5A 2021-09-10 2022-04-11 药物组合物及其用途 Pending CN117957000A (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
PCT/CN2021/117692 WO2023035223A1 (zh) 2021-09-10 2021-09-10 药物组合物及其用途
CNPCT/CN2021/117692 2021-09-10
PCT/CN2022/086053 WO2023035611A1 (en) 2021-09-10 2022-04-11 Pharmaceutical composition and use thereof

Publications (1)

Publication Number Publication Date
CN117957000A true CN117957000A (zh) 2024-04-30

Family

ID=85507161

Family Applications (1)

Application Number Title Priority Date Filing Date
CN202280061191.5A Pending CN117957000A (zh) 2021-09-10 2022-04-11 药物组合物及其用途

Country Status (10)

Country Link
US (1) US20240366600A1 (https=)
EP (1) EP4398909A4 (https=)
JP (1) JP2024533423A (https=)
KR (1) KR20240074779A (https=)
CN (1) CN117957000A (https=)
AU (1) AU2022341942A1 (https=)
CA (1) CA3231192A1 (https=)
IL (1) IL311331A (https=)
MX (1) MX2024002822A (https=)
WO (2) WO2023035223A1 (https=)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN116159062A (zh) * 2021-11-24 2023-05-26 上海艾力斯医药科技股份有限公司 药物组合物及其用途
JP2025510910A (ja) * 2022-03-31 2025-04-15 アストラゼネカ・アクチエボラーグ 癌の処置のための、ａｋｔ阻害剤との組み合わせにおける上皮成長因子受容体（ｅｇｆｒ）チロシンキナーゼ阻害剤
WO2024059962A1 (en) * 2022-09-19 2024-03-28 Shanghai Allist Pharmaceuticals Co., Ltd. Pharmaceutical composition and use thereof
CN116478138A (zh) * 2023-04-21 2023-07-25 江苏艾力斯生物医药有限公司 一种甲磺酸伏美替尼原料药的结晶方法
CN116893086A (zh) * 2023-04-28 2023-10-17 江苏艾力斯生物医药有限公司 一种靶向药甲磺酸伏美替尼片的模拟片及其制备方法
CN117547536A (zh) * 2023-11-15 2024-02-13 江苏艾力斯生物医药有限公司 一种药物组合物、其制备方法及应用

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN105315259B (zh) * 2014-07-29 2018-03-09 上海艾力斯医药科技有限公司 吡啶胺基嘧啶衍生物、其制备方法及应用
CN107163026B (zh) * 2016-03-07 2019-07-02 上海艾力斯医药科技有限公司 吡啶胺基嘧啶衍生物的盐及其制备方法和应用
CN110590749B (zh) * 2016-03-07 2020-11-06 上海艾力斯医药科技股份有限公司 吡啶胺基嘧啶衍生物甲磺酸盐的结晶形式及其制备和应用

Also Published As

Publication number Publication date
KR20240074779A (ko) 2024-05-28
AU2022341942A1 (en) 2024-05-02
EP4398909A1 (en) 2024-07-17
CA3231192A1 (en) 2023-03-16
IL311331A (en) 2024-05-01
EP4398909A4 (en) 2025-08-13
WO2023035223A1 (zh) 2023-03-16
WO2023035611A1 (en) 2023-03-16
JP2024533423A (ja) 2024-09-12
US20240366600A1 (en) 2024-11-07
MX2024002822A (es) 2024-05-03

Similar Documents

Publication Publication Date Title
CN117957000A (zh) 药物组合物及其用途
JP7611855B2 (ja) ユーイング肉腫治療用キノリン系化合物又はその薬学的に許容される塩
US11419862B2 (en) Quinoline derivative for treatment of nasopharyngeal carcinoma
CN112043702A (zh) 用于联合治疗结直肠癌的喹啉类化合物
WO2023093663A1 (en) Pharmaceutical composition and use thereof
EP3973964A1 (en) Quinoline derivative used for combination treatment of small cell lung cancer
WO2024061203A1 (en) Pharmaceutical composition and use thereof
US12377089B2 (en) Quinoline derivative used for soft tissue sarcoma combination therapy
US20220211694A1 (en) Quinoline derivatives for treatment of head and neck cancer
HK40110967A (zh) 药物组合物及其用途
HK40116696A (zh) 药物组合物及其用途
CN111821302A (zh) 用于联合治疗软骨肉瘤的喹啉类化合物
RU2827402C2 (ru) Фармацевтическая композиция, содержащая пиридинаминное соединение, и ее применение при ros1-положительном немелкоклеточном раке легкого
CN112294814A (zh) 用于治疗胶质母细胞瘤的喹啉衍生物
HK40065487A (en) Quinoline derivative used for soft tissue sarcoma combination therapy
HK40067323A (en) Quinoline derivative and epirubicin used for soft tissue sarcoma combination therapy

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
REG Reference to a national code

Ref country code: HK

Ref legal event code: DE

Ref document number: 40110967

Country of ref document: HK